SOLTF (Nxera Pharma Co) Net Margin %: -11.44% (As of Mar. 2026)

What is Nxera Pharma Co Net Margin %?

Nxera Pharma Co SOLTF 84 Net Margin % is -11.44% as of Mar. 2026. GuruFocus rates SOLTF with a GF Score™ of 84/100 and a GF Value™ of $7.77 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 947 Biotechnology companies, Nxera Pharma Co ranks better than 57.34% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Nxera Pharma Co's Net Income for the three months ended in Mar. 2026 was $-4.8 Mil. Nxera Pharma Co's Revenue for the three months ended in Mar. 2026 was $41.9 Mil. Therefore, Nxera Pharma Co's net margin for the quarter that ended in Mar. 2026 was -11.44%.

The historical rank and industry rank for Nxera Pharma Co's Net Margin % or its related term are showing as below:

SOLTF' s Net Margin % Range Over the Past 10 Years
Min: -56.34 Med: -7.17 Max: 48.42
Current: -42.31

SOLTF's Net Margin % is ranked better than
57.34% of 947 companies
in the Biotechnology industry
Industry Median: -89.56 vs SOLTF: -42.31

Nxera Pharma Co (OTCPK:SOLTF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Nxera Pharma Co Net Margin % Related Terms

Nxera Pharma Co Net Margin % Historical Data

* Premium members only.

The historical data trend for Nxera Pharma Co's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nxera Pharma Co Net Margin % Chart

Nxera Pharma Co Annual Data

Trend

Mar16

Mar17

Mar18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Net Margin %

Get a 7-Day Free Trial

5.74

2.45

-56.35

-16.78

-42.31

Nxera Pharma Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Net Margin %	Get a 7-Day Free Trial															-11.44	-28.13	-24.76	-99.41	-11.44

SOLTF vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Nxera Pharma Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nxera Pharma Co Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Net Margin % distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Net Margin % falls into.

Save Embed

84GF Score

Nxera Pharma Co Ltd SOLTF

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Nxera Pharma Co Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Nxera Pharma Co's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin	=	Net Income (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-80.364	/	189.943
	=	-42.31 %

Nxera Pharma Co's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-4.789	/	41.87
	=	-11.44 %

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of -11.44% mean?

Nxera Pharma Co (SOLTF) has a Net Margin % of -11.44% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Nxera Pharma Co and its competitors. According to the industry distribution chart, Nxera Pharma Co ranks #404 out of 947 companies in the Biotechnology industry, placing it in the top 42.7%.

Is Nxera Pharma Co's Net Margin % too high?

Nxera Pharma Co's current Net Margin % is -11.44%. Based on the distribution chart, Nxera Pharma Co ranks #404 out of 947 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nxera Pharma Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Nxera Pharma Co's Net Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Nxera Pharma Co ranks #404 out of 947 companies for Net Margin %. This puts Nxera Pharma Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Nxera Pharma Co and its competitors. Nxera Pharma Co's current Net Margin % is -11.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Nxera Pharma Co stock overvalued right now?

Based on GuruFocus' analysis, Nxera Pharma Co (SOLTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.77, compared to a current price of $6.37 — trading 18% below its estimated fair value. The current Net Margin % is -11.44%. Nxera Pharma Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For Nxera Pharma Co (SOLTF), the current Net Margin % is -11.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nxera Pharma Co (SOLTF) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued. The current stock price of $6.37 is trading 18% below its estimated GF Value™ of $7.77. GuruFocus considers Nxera Pharma Co to be Modestly Undervalued.

Key valuation signals for SOLTF:

Net Margin %: -11.44%
GF Value™: $7.77 vs. price of $6.37 (18% below fair value)
GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the SOLTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nxera Pharma Co Business Description

Industry Healthcare Biotechnology

Comparable Companies TSE:4592 TSE:4588 TSE:4974 TSE:2160 TSE:4587 TSE:4593 TSE:4894 TSE:219A TSE:504A TSE:7774 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 4565:Japan

Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052

Website https://www.nxera.life

Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).

84GF Score

Get the complete analysis for SOLTF

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.37

Price

$7.77

GF Value

View SOLTF Analysis

See Net Margin % data for all stocks →